Dr. Bunn on the MYSTIC Trial for Lung Cancer

Paul A. Bunn Jr, MD
Published: Wednesday, Aug 30, 2017



Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Further details are needed from this trial in order to come to a conclusion regarding its results, states Bunn.

This study did not meet its primary endpoint of progression-free survival, explains Bunn. The study investigated chemotherapy versus durvaluamab (Imfinzi) and tremilumumab versus durvalumab alone. There were a number of different subsets that need to be analyzed further.
 


Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Further details are needed from this trial in order to come to a conclusion regarding its results, states Bunn.

This study did not meet its primary endpoint of progression-free survival, explains Bunn. The study investigated chemotherapy versus durvaluamab (Imfinzi) and tremilumumab versus durvalumab alone. There were a number of different subsets that need to be analyzed further.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x